The effect of total hip replacement on employment in patients with ankylosing spondylitis

He, C.; He, Xiaokang; Tong, Wenwen; Zheng, Wei; Zhang, Tianfang; Zhao, Jun-Wu; Xu, Weidong

doi:10.1007/s10067-016-3431-6

Cited by 16 publications

(32 citation statements)

References 33 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…[ 7 – 9 ] It is estimated that about 0.1% to 1.8% people affect this disorder and onset of symptoms commonly manifest in males between 15 and 25 years old. [ 10 , 11 ] To date, its etiology remains not fully elucidated. [ 12 , 13 ]…”

Section: Introductionmentioning

confidence: 99%

Efficacy of alendronate for the treatment of ankylosing spondylitis

Tang¹,

Tang

et al. 2020

Medicine

View full text Add to dashboard Cite

Background: Ankylosing spondylitis (AS) is a very tricky orthopedic disorder. If such condition cannot be managed fairly well, it may significantly affect quality of life and even leads to disability among such population. A variety of studies have reported that alendronate is utilized for the treatment of AS. However, their results are still contrary, and no systematic review has addressed on this topic. Thus, this study will systematically assess the efficacy and safety of alendronate for the treatment of patients with AS. Methods: A comprehensive literature search will be performed from the below electronic databases from their commencement to the January 31, 2020 without language and publication status limitations: PubMed, Embase, Cochrane Library, Web of Science, Allied and Complementary Medicine Database, WANGFANG, and China National Knowledge Infrastructure. Only randomized controlled trials focusing on the alendronate for the treatment of patients with AS will be considered for inclusion in this study. Two authors will independently select all identified records, extract essential data from all included studies, and appraise study quality for each eligible trial using Cochrane risk of bias. If any differences occur, another experienced author will be invited to solve them by discussion and a consensus decision will be made. We will implement RevMan 5.3 software to analyze the extracted data. Results: This study will summarize high-quality randomized controlled trials to assess the efficacy and safety of alendronate for the treatment of patients with AS through primary outcome of bone densitometry; and secondary outcomes of pain intensity, quality of life, disease activity, functional status, and adverse events. Conclusion: This study will provide evidence to help determine whether alendronate is an effective and safe management for patient with AS or not. Study registration: INPLASY202040153.

show abstract

Section: Introductionmentioning

confidence: 99%

Efficacy of alendronate for the treatment of ankylosing spondylitis

Tang¹,

Tang

et al. 2020

Medicine

View full text Add to dashboard Cite

show abstract

“…It primarily affects the spine and pelvis but peripheral arthritis and enthesitis are also common features. 1 The mean age of onset of symptoms is between 15 and 25 years and it is more common in males. 2 Approximately 0.1% to 1.8% of people are affected.…”

Section: Introductionmentioning

confidence: 99%

“…Severe disability and functional impairment can result rapidly due to a combination of axial spine and hip involvement. 1…”

Section: Introductionmentioning

confidence: 99%

Bilateral total hip arthroplasty in ankylosing spondylitis: a systematic review

2019

View full text Add to dashboard Cite

Ankylosing Spondylitis (AS) can commonly involve the hip joint and cause significant mobility problems. Total hip arthroplasty (THA) on a single side alone will not restore mobility in patients with bilateral disease. We performed a systematic review of the available literature to determine the changes in objective outcome measures and complications of bilateral THA in patients with advanced AS. Four studies, a total of 114 THAs, were included in the study. The average patient age was 32.9 years and the average follow-up time was 59.5 months. All studies reported a significant improvement in hip function, patient satisfaction and patient mobility following bilateral THA. Harris Hip Score (HHS) improved by a mean of 60.6 points post-operatively. Complications included five intra-operative fractures (4.4%) and three transient nerve palsies (2.6%). There were two dislocations (1.8%) that were successfully managed with closed reduction. Seven hips required revision, with the most common cause being aseptic loosening. Twelve hips (10.5%) developed heterotopic ossification consistent with Brooker Class 1 or 2 with no reports of re-ankylosis. This review suggests that bilateral THA is a safe and effective treatment of advanced hip disease in AS. Attention must be paid to the highly demanding technical aspects of this procedure to reduce the risk of significant complications. Debate still exists on the ideal prosthesis, fixation method and approach to use but this review presents data from several series of uncemented prostheses that have good post-operative results. Cite this article: EFORT Open Rev 2019;4:476-481. DOI: 10.1302/2058-5241.4.180047

show abstract

“…It is characterized by in ammation of spine and the sacroiliac joints [4][5][6], which causes structural and functional impairments of those joints and results in poor quality of life [7][8][9]. It is estimated that about 0.1% to 1.8% people affect this disorder and onset of symptoms commonly manifest in males between 15 and 25 years old [10][11].…”

Section: Introductionmentioning

confidence: 99%

Efficacy of alendronate for the treatment of ankylosing spondylitis: a protocol for systematic review and meta-analysis

Tang

et al. 2020

Preprint

View full text Add to dashboard Cite

Background Ankylosing spondylitis (AS) is a very tricky orthopedic disorder. If such condition can not be managed fairly well, it may significantly affect quality of life and even leads to disability among such population. A variety of studies have reported that alendronate is utilized for the treatment of AS. However, their results are still contrary, and no systematic review has addressed on this topic. Thus, this study will systematically assess the efficacy and safety of alendronate for the treatment of patients with AS. Methods A comprehensive literature search will be performed from the below electronic databases from their commencement to the January 31, 2020 without language and publication status limitations: PUBMED, EMBASE, Cochrane Library, Web of Science, Allied and Complementary Medicine Database, WANGFANG, and China National Knowledge Infrastructure. Only randomized controlled trials (RCTs) focusing on the alendronate for the treatment of patients with AS will be considered for inclusion in this study. Two authors will independently select all identified records, extract essential data from all included studies, and appraise study quality for each eligible trial using Cochrane risk of bias. If any differences occur, another experienced author will be invited to solve them by discussion and a consensus decision will be made. We will implement RevMan 5.3 software to analyze the extracted data. Results This study will summarize high quality RCTs to assess the efficacy and safety of alendronate for the treatment of patients with AS through primary outcome of bone densitometry; and secondary outcomes of pain intensity, quality of life, disease activity, functional status, and adverse events. Conclusions This study will provide evidence to help determine whether alendronate is an effective and safe management for patient with AS or not.

show abstract

The effect of total hip replacement on employment in patients with ankylosing spondylitis

Cited by 16 publications

References 33 publications

Efficacy of alendronate for the treatment of ankylosing spondylitis

Efficacy of alendronate for the treatment of ankylosing spondylitis

Bilateral total hip arthroplasty in ankylosing spondylitis: a systematic review

Efficacy of alendronate for the treatment of ankylosing spondylitis: a protocol for systematic review and meta-analysis

Contact Info

Product

Resources

About